The JAK2 inhibitor Momelotenib and the MDM2 inhibitor NVP-HDM201 confirmed their activity, respectively, in JAK2-mutated AML and NPM1 and TP53 wild type settings, while Menin inhibitors were active in MLL and NPM1 comutated FLT3AML. Here, MEN1 is linked to acute myeloid leukemia.